Viventia is developing and advancing the next generation of human antibody-based therapeutics for use in oncology. Our approach combines the specificity of an antibody with the potency of a cytotoxic payload to provide targeted therapies for the safer and more efficacious treatment of cancer patients. Viventia has developed a potent payload, deBouganin, that when coupled to a targeting antibody can effectively kill cancer cells without harming normal cells. This differential targeting enhances the therapeutic potential of our drugs and provides prolonged clinical benefit. The versatile deBouganin payload has been chemically conjugated to full length antibodies as well as fused to numerous antibody fragments and has been found to be safe and efficacious in the clinic. more... See more text